Twenty-nine consecutive patients with high-risk hematological malignancy aged from 3 to 58 years underwent an unmanipulated graft from an HLA-identical sibling after an irradiation-free preparative regimen consisting of idarubicin (IDA), 21 mg/m 2 /day administered by continuous infusion on days −12 and −11, followed by busulphan (BU), 4 mg/kg/day orally from day −7 to −4, and cyclophosphamide (CY), 60 mg/kg/day intravenously on days −3 and −2 (IDA-BUCY2). Most clinically relevant extra-hematological regimen-related toxicities consisted of stomatitis observed in all subjects and hemorrhagic cystitis occurred in five cases (17%) within 100 days after transplant. Six patients (21%) developed a grade 2 acute graft-versus-host disease (GVHD) and three (10%) a grade 3 or 4; extensive chronic GVHD was assessed in nine of 22 (41%) evaluable patients. So far, 12 patients have died and 17 are alive, 16 of whom disease-free, 5-41 months after transplant (median, 15 months). The causes of death were related to GVHD in three patients, to sepsis in one and to disease recurrence in the remaining eight. At present, only one of nine relapsed patients is alive. For all patients the actuarial probability of survival (OS) at 1 and 2 years ± standard error (s.e.) was 63 ± 9% and 52 ± 10%, respectively. The actuarial probabilities of diseasefree survival (DFS), relapse and transplant-related mortality (TRM) at both 1 and 2 years ± s.e. were 53 ± 9%, 35 ± 9% and 16 ± 7%, respectively. These results are encouraging but not substantially different from those obtained in 28 patients with malignancy in advanced phase transplanted after the standard BUCY2 regimen, who had an actuarial probability of OS, DFS, relapse and TRM projected at 10 years ± s.e. of 54 ± 10%, 57 ± 9%, 36 ± 9% and 11 ± 6%, respectively. Although the retrospective comparison between the two groups does not seem to show any advantage in the use of the IDA intensified regimen, only a prospective randomized trial could answer this question.
Introduction
The combination of high-dose cyclophosphamide (CY) and total body irradiation (TBI) has been long used as the standard regimen to prepare patients with hematological malignancy for an allogeneic bone marrow transplantation (BMT). 1 To reduce the disadvantages related to the use of TBI, which requires special equipment and induces both acute and late toxic effects, Santos et al 2 firstly introduced an irradiation-free regimen consisting of 4 mg/kg of oral busulphan (BU) for 4 days followed by 50 mg/kg of intravenous (i.v.) CY for 4 days (BUCY4). Tutschka et al 3 lowered the total dose of CY to 120 mg/kg administered over 2 days (BUCY2) obtaining similar rates of disease-free survival (DFS) in patients transplanted for leukemia. Two prospective randomized trials compared BUCY2 to TBI-based regimens in patients with advanced malignancies undergoing an allogeneic BMT. 4, 5 Ringden et al reported an increased transplant-related mortality (TRM) and a decreased DFS in patients with leukemia transplanted beyond the first complete remission (CR) or first chronic phase (CP) and conditioned with BUCY2 as compared to those prepared with CY-TBI. In contrast, Blume et al 4 did not find any significant difference in terms of DFS between two treatment groups using BUCY2 or fractionated TBI followed by highdose etoposide, both in 'good-risk' (patients in second CR of their acute leukemia or in accelerated phase (AP) of chronic myeloid leukemia (CML), and in 'poor-risk' patients (further advanced stages of leukemia). Moreover, a large retrospective study produced by the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) demonstrated that among allograft recipients with 'intermediate' acute leukemia (second or later remission, first relapse) there were no significant differences between patients prepared with BU-CY or CY-TBI regarding TRM, relapse rate (RR) and DFS. 6 Using any of these conventional preparative regimens, the EBMT study reported a 2-year probability of DFS ranging from 32 to 47%, because of a considerable RR ranging from 44 to 55%, 6 whereas in the Southwest Oncology Group study less than 30% of patients with leukemia transplanted in more advanced stages (у3rd CR, primary refractory leukemia, florid relapse, blastic crisis (BC)) survived relapsefree at 3 years. 4 Over the years, several approaches have been attempted to intensify the BU-CY combination in order to reduce the RR which remains the major reason for failure following allogeneic BMT in advanced malignancies. [7] [8] [9] [10] [11] [12] Most of these intensified conditioning regimens did not significantly improve the outcome and conferred no advantage over the BUCY2 standard regimen in terms of DFS, leading to severe TRM without reducing the RR. At the same time, the Nijmegen Group has been exploring the addition of idarubicin (IDA) to conventional preparative regimens, reporting interesting results in recipients of T cell-depleted graft. [13] [14] [15] [16] Here, we report our experience using the IDA-BUCY2 regimen on a series of 29 consecutive patients with high-risk hematological malignancies, receiving an unmanipulated graft from an HLAidentical sibling. Moreover, we provide the results achieved with BUCY2 in 28 high-risk patients who underwent an unmanipulated BMT from an HLA-identical sibling between December 1988 and June 1996.
Patients and methods

Patients and donors
Between June 1996 and May 1999, 29 consecutive patients with high-risk hematological malignancies underwent an allogeneic stem cell transplantation following the BUCY2 conditioning regimen intensified with IDA (Table 1) . Our high-risk criteria included first CR with unfavorable cytogenetic abnormalities, primary refractory disease, florid relapse, second or Table 1 Characteristics of 57 high-risk patients receiving allogeneic transplants following conditioning with IDA-BUCY2 (n = 29) or BUCY2 (n = 28) 
IDA-BUCY2 BUCY2
Conditioning regimen and supportive care
The conditioning regimen consisted of IDA at the dose of 21 mg/m 2 /day, administered by continuous infusion on days −12 and −11, followed by BU at the dose of 16 mg/kg administered orally in four divided daily doses from day −7 to −4 and i.v. CY given over 90 min at the dose of 60 mg/kg/day on Leukemia days −3 and −2. Uroepithelial protection was achieved with i.v. hydration and continuous bladder irrigation during CY administration. All subjects received phenobarbital at the dose of 2 mg/kg daily beginning 24 h before the first dose of BU until transplant to prevent seizures; the dose was reduced and discontinued within 2 days after transplant. All patients were cared for in private rooms with positive pressure and high efficiency particle filtration air system (HEPA). Antinfectious prophylaxis consisted of acyclovir, ciprofloxacin and fluconazole. No patient received prophylactic i.v. immunoglobulins, gancyclovir or foscarnet and hemopoietic growth factors. Total parenteral nutrition was provided as needed. Day 0 was the day of donor cell infusion. The first of 3 consecutive days with granulocyte count у0.5 × 10 9 /l was defined as the day of engraftment. The retrospective patient series received the BUCY2 regimen without IDA and the same antinfectious prophylaxis and supportive care.
Source of stem cells
For adults the stem cell source was picked out on the basis of donor preference, whereas bone marrow (BM) was ordinarily collected for donors aged less than 18 years. So far, the stem cell source was BM in 16 cases. In the remaining 13 cases, the peripheral blood stem cells (PBSC) were collected after mobilization following administration to the donors of glycosilate recombinant human granulocyte colony-stimulating factor at the dose of 10 g/kg daily in two divided doses subcutaneously for 3 days. With a target of CD34 + cells to be collected у4 × 10 6 /kg of the recipient, the number of leukaphereses performed was one for 12 donors, and two for one donor. The harvested cells from either BM or peripheral blood were infused unmanipulated on the same day of collection. In the retrospective group the stem cell source was BM in each case.
Graft-versus-host disease (GVHD) prophylaxis
All patients received cyclosporin A (CsA) administered at the dose of 3 mg/kg/day intravenously from day −1 and then at 12.5 mg/kg daily orally as soon as the oral route was tolerated maintaining trough levels at 200-400 ng/ml. Starting on day 50, oral CsA was tapered by 5% weekly and discontinued on day 180, unless otherwise specified. A short course of methotrexate (MTX) was given to 24 adult patients; MTX was administered intravenously at the dose of 15 mg/m 2 on day 1 and 10 mg/m 2 on days 3, 6 and 11. For the historical group, the GVHD prophylaxis consisted of CsA + MTX ± 6-methylprednisolone in 15 patients and of CsA ± 6-methylprednisolone in the other 13 patients. Acute and chronic GVHD was diagnosed and graded according to the established criteria.
17,18
Grading of toxicity
Regimen-related toxicity (RRT) was graded according to the criteria published by Bearman et al. 19 If organ damage was not identified as the result of infection, GVHD or drug therapy, it was assumed to be caused by the preparative regimen and was graded as such.
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Study definitions and statistical analysis
The follow-up data were analyzed as of 31 October 1999. Overall survival (OS) was defined as the time from the date of transplant to death from any cause or to the last follow-up. DFS was defined as the time from the date of transplant to disease relapse/progression or to death in CR or to the last follow-up in CR. TRM was defined as any cause of death other than the underlying disease. The actuarial probabilities of survival, relapse and TRM were estimated by the method of Kaplan and Meier. 20 
Results
Engraftment
All patients engrafted. The median number of nucleated infused cells (NC) was 2.63 × 10 8 /kg (range, 0.9-5.37 NC) and 11.8 × 10 
Early regimen-related toxicity
No patient developed grade 3 (life-threatening) or 4 (fatal) RRT. Oropharingeal mucositis was the most common complication; it was observed in all patients and graded as grade 2 (moderate, requiring treatment) in 23 of them (79%) and as grade 1 (mild) in the remaining six (21%). Hemorrhagic cystitis occurred in five patients (17%) within 100 days from transplant, but in only two of them (7%) it has been considered as a moderate regimen-related hemorrhagic cystitis according to Bearman criteria. Finally, two patients developed grade 2 cardiac and neurologic toxicity, respectively. Venoocclusive disease (VOD) according to Jones's criteria 21 was never observed as well as RRT greater than grade 1 in each other organ system.
GVHD
All patients except two had a good compliance with the planned dose schedule for CsA and MTX. Eight patients (27%) developed grade 1 acute GVHD, six (21%) grade 2 and three (10%) grade 3 or 4. Extensive chronic GVHD was assessed in nine of 22 (41%) evaluable patients (in seven of 10 and in two of 12 evaluable recipients of PBSC and BM, respectively), whereas no patient experienced limited chronic GVHD.
Outcome
For all patients the median follow-up after transplant was 10 months. Seventeen patients are alive at a median of 15 months (range, 5-41 months) and 12 died from 1 to 13 months after transplant (Table 2) . Nine patients relapsed between 43 and 295 days after transplant (median, 90 days); eight of them died at a median of 127 days (range, 16-307 days) from relapse and 1 (UPN 433) is alive in third CR after chemotherapy and donor lymphocyte infusion (DLI) at 199 days from relapse. Relapses occurred in four patients with ALL (three allografted in second and one in fourth CR), in three patients with CML (two transplanted in BC and one in second CP) and in two patients allografted in second relapse of AML and in second PR of T-lymphoblastic lymphoma, respectively. No patient with chronic GVHD relapsed as compared to four of the 13 (31%) without it. Four of 12 deaths (33%) occurred from causes other than recurrence of the underlying disease: two of three patients with grades 3-4 acute GVHD died of this complication at days 43 and 85 (none of them had discontinued CsA as a consequence of RRT), one patient with extensive chronic GVHD died of multi-organ failure at day 251 and one died of sepsis. As for only acute leukemias, one of nine AMLs relapsed as compared to four of nine ALLs. Among these five relapsed patients, one (20%) had acute GVHD greater than grade 1 and three did not have it at all, while chronic GVHD was not evaluable in three patients because of early relapse and absent in the other two. Among 13 relapse-free patients, four (31%) had acute GVHD greater than grade 1 and six did not have it at all, while chronic GVHD was assessed in seven of 11 (64%) evaluable patients. There was a similar proportion of marrow and PBSC grafts between the two groups of relapsed and relapse-free acute leukemic patients. For all patients the actuarial probability of OS at 1 and 2 years was 63% (95% confidence interval (CI), 45-81%) and 52% (95% CI, 32-72%), respectively. The actuarial probabilities of DFS, relapse and TRM at both 1 and 2 years were 53% (95% CI, 35-71%), 35% (95% CI, 17-53%) and 16% (95% CI, 2-30%), respectively ( Figure 1) . The 2-year probability of DFS and relapse for AML was 65% and 11%, respectively, whereas the 1-year probability of DFS and relapse for ALL was 44% and 49%, respectively.
Outcome of BUCY2 patient group
The median follow-up of the historical group was 54 months. Sixteen patients of this group are alive at a median of 91 months (range, 43-130 months) and 12 died from 1 to 93 months after transplant. The incidence of acute and chronic GVHD was not significantly different as compared to that observed in the IDA-BUCY2 patient group. Nine patients relapsed between 77 and 925 days after transplant (median, 155 days); all relapsed patients died. Relapses occurred in four patients with ALL and in five with AML. Also in the BUCY2 group, no patient with chronic GVHD relapsed as compared to six of the 15 (40%) without it. Three of 12 deaths (25%) occurred from causes related to the transplant procedure (acute GVHD and RRT). For the historical group of patients, the actuarial probabilities of OS, DFS, relapse and TRM at 2 years were 68% (95% CI, 50-86%), 61% (95% CI, 43-79%), 32% (95% CI, 14-50%) and 11% (95% CI, 0-23%), respectively ( Figure 2) . The 2-year probability of DFS and relapse for AML was 54% and 42%, whereas the 1-year probability of DFS and relapse for ALL was 67% and 27%, respectively.
Discussion
During the last 13 years the Nijmegen Group has been exploring the pre-transplant therapy intensification by adding anthracycline to the standard conditioning regimens in patients undergoing an allogeneic marrow graft depleted of lymphocytes. [13] [14] [15] [16] In the retrospective study of 181 patients with standard-risk leukemia reported by Schaap et al, 16 the 5-year probability of relapse was significantly lower (26% vs 52%; P = 0.015) and the DFS significantly higher (56% vs 36%; Alive in 3rd CR.
Figure 1
Probability of transplant-related mortality, disease-free survival and relapse in 29 high-risk patients conditioned with IDA-BUCY2. P = 0.004) in the group receiving a regimen intensified with anthracycline (n = 116) as compared to the control group (n = 65), without an increased TRM. However, the intensified conditioning regimen included TBI in 109 patients and only seven patients were prepared with IDA-BUCY2; all patients
Leukemia were transplanted with a T cell-depleted marrow. We extended the use of IDA-BUCY2 regimen to 29 patients with high-risk hematological malignancies undergoing an unmanipulated transplant. The choice of IDA in combination with BUCY2 was mainly based on the evidence provided for the
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Figure 2
Probability of transplant-related mortality, disease-free survival and relapse in 28 high-risk patients conditioned with BUCY2.
major anti-leukemic activity against the multidrug-resistant cell compartment and on the lower cardiac toxicity of IDA over the other anthracyclines. 22 The IDA treatment schedule was based on the Nijmegen Group experience: a total dose of IDA 42 mg/m 2 administered by continuous infusion on days −12 and −11 was associated with less severe mucositis and faster hematopoietic recovery, probably due to the lower concentration of idarubicinol at the time of transplant. 13, 15 The most frequent complication in our patients was stomatitis, comparable in terms of incidence and severity to that observed by Donnelly et al 23 in recipients of T cell-depleted marrow conditioned with a TBI-based regimen intensified with IDA. The incidence of hemorrhagic cystitis was similar to that reported by Sencer et al 24 in a large retrospective study of transplanted patients who were prepared with BU or TBIbased standard regimens. Congestive heart failure responsive to treatment occurred in just one patient heavily pretreated, who had already developed an episode of cardiac toxicity before BMT. No patient experienced VOD or a life-threatening or fatal toxicity caused by this regimen. Therefore, 16% of TRM of our study may be partly explained by the low extrahematological RRT. Forty-five percent of patients received PBSC. Considering the provided efficacy of PBSC in reconstituting the hemopoietic and immune system more rapidly than allogeneic BMT without a significant increase in the incidence and severity of acute GVHD, 25, 26 the different stem cell source may have had a potential impact on the low TRM, but the low number of events (BM = 3; PBSC = 1) does not allow any conclusion. Moreover, although chronic GVHD occurred in 70% of evaluable PBSC recipients compared to 17% of BM, this difference did not affect the relapse incidence in the two groups which were comparable concerning the disease phase at the time of transplant. The apparent lack of correlation between the source of stem cells and the likelihood of recurrence disease could be explained by the earliness of relapse in this patient population. All relapses occurred within the first year after transplant with an actuarial probability of 35%. This result could have been influenced by having enrolled the lowrisk AMM, whose median survival reported by Dupriez et al 27 is 112 months in the case of normal karyotype, but one patient alone (UPN 364) does not affect the overall outcome. Moreover, the good compliance with GVHD prophylaxis observed excludes the possibility that an early CsA dose taper might have affected the outcome in terms of increased graft-versusleukemia (GVL) effect, as suggested by Abraham et al. 28 The results of the IDA-BUCY2 regimen are very similar to those obtained in 28 high-risk patients undergoing an unmanipulated BMT from an HLA-identical sibling after BUCY2 conditioning between 1989 and 1996. However, no definitive conclusion can be drawn from this retrospective comparison and only a prospective randomized trial could answer the question. Although our patient series was not homogeneous as to the diagnosis of the underlying disease, most of them were transplanted for acute leukemia; therefore, overall results significantly depended on leukemic patient outcome. Taking this fact into account, 67% of cases of disease recurrence had lymphoid origin, including the case of lymphoid BC of CML (UPN 365, 409, 412, 430, 433, 451); in particular, four ALLs relapsed as compared to one AML, but no difference in terms of acute or chronic GVHD was observed between ALL and AML groups.
Because of the small number of patients we are not able to establish whether the different risk of relapse between AML and ALL should be referred to a major antileukemic activity of regimen or to a major GVL effect against myeloid compared to lymphoid blasts. However, our results suggest a closer correlation between the probability of relapse-free survival and chronic compared to acute GVHD. In fact, whereas we did not observe any difference in terms of acute GVHD between relapsed and relapse-free acute leukemic patients in both the study groups, among the relapse-free survivors, 64% in the IDA group and 43% in the historical group had chronic GVHD compared to none of the relapsed patients. This difference does not achieve a statistical significance and may partly be due to earlier relapses occurring in high-risk patients. However, in this respect, this observation is consistent with the EBMT study of Ringdèn et al 29 on GVL effect in allogeneic BMT recipients with acute leukemia in whom the combination CsA-MTX was used as GVHD prophylaxis. The EBMT study reported that, in patients with intermediate stage of leukemia (у2nd remission or first relapse) with previous acute GVHD, those with extensive chronic GVHD had a reduced IDA-BUCY2 regimen for BMT in high-risk patients A Mengarelli et al 2057 probability of relapse (P = 0.05); in this way, a stronger GVL effect which may be induced by extensive disease seems to be required to eradicate leukemic cells in more advanced stages of leukemia and to reduce the risk of relapse. The correlation between the lack of chronic GVHD and relapse poses the question of the necessity to intensify preparative regimens at all over adding immuno-modulator approaches to existing intensive regimens. Recently, on the basis of several reports which have shown that DLI can eradicate some malignancies that relapse after conventional BMT without high-dose induction therapy, the emphasis has switched toward the opposite of the preparative regimen intensification, such as the investigation of 'mini-transplant' and DLI. 30 This approach, reducing RRT and the risk of acute GVHD through a lower cytokine release, could allow the extension of the allografting procedure to older patients or patients with pre-existing organ dysfunction. However, responses after DLI have frequently been gradual in onset over a period of 4-12 months. In this respect, in high-risk patients the use of intensive conditioning regimen appears useful, considering that the relapses tend to be earlier, with a median of 90 days in our population. Nevertheless, considering the low RRT of IDA-BUCY2, the addition of immuno-modulator treatments such as preventive DLI could be practicable and allow the harnessing of the graftversus-tumor effect early. Finally, Grigg et al 31 in a large retrospective study on factors affecting the outcome of allogeneic BMT for adults with refractory or relapsed acute leukemia, have confirmed the very poor prognosis of 383 patients with high-risk features similar to ours, reporting an OS of 30%, 23%, 18% and 14% at 1, 2, 5 and 10 years, respectively. In conclusion, the IDA-BUCY2 regimen allows a 2-year DFS probability of 53% without an unacceptable increase of RRT and seems particularly promising in advanced AMLs. However, the antileukemic properties of this intensified regimen should be confirmed on a larger number of patients and on a longer follow-up. Aiming at answering this question, a cooperative multi-centric randomized phase III study is now ongoing to assess the role of IDA intensification in the pretransplant conditioning regimen for patients with lymphoid and myeloid malignancies with high-risk of relapse.
